Oppenheimer Upgrades DiaMedica Therapeutics to Outperform, Announces $7 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Francois Brisebois upgraded DiaMedica Therapeutics (NASDAQ:DMAC) from Perform to Outperform and announced a $7 price target.
June 22, 2023 | 11:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DiaMedica Therapeutics (NASDAQ:DMAC) has been upgraded to Outperform by Oppenheimer, with a $7 price target.
The upgrade from Perform to Outperform by Oppenheimer analyst Francois Brisebois indicates a positive outlook for DiaMedica Therapeutics. The announcement of a $7 price target suggests potential upside for the stock, which may lead to short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100